In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy

Molecular Therapy

Volumn 19, Issue 8, 2011, Pages 1511-1520

  Liu, Chao Lien ^a   Ye, Peiqing ^a   Yen, Benjamin C ^a   Miao, Carol H ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; INTERLEUKIN 2; INTERLEUKIN 2 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; GENE THERAPY; HEMOPHILIA A; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; PLASMID MEDIATED GENE THERAPY; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

MUS;

EID: 79961026869     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.61     Document Type: Article

References (50)

1. Antonarakis, SE, Youssoufian, H and Kazazian, HH Jr (1987). Molecular genetics of hemophilia A in man (factor VIII deficiency). Mol Biol Med 4: 81-94.
2. Zhang, AH, Skupsky, J and Scott, DW (2009). Factor VIII inhibitors: risk factors and methods for prevention and immune modulation. Clin Rev Allergy Immunol 37: 114-124.
3. VandenDriessche, T, Vanslembrouck, V, Goovaerts, I, Zwinnen, H, Vanderhaeghen, ML, Collen, D et al. (1999). Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIIIdeficient mice. Proc Natl Acad Sci USA 96: 10379-10384. (Pubitemid 29422566)
4. Powell, JS, Ragni, MV, White, GC 2nd, Lusher, JM, Hillman-Wiseman, C, Moon, TE et al. (2003). Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood 102: 2038-2045. (Pubitemid 37122377)
5. Ye, P, Thompson, AR, Sarkar, R, Shen, Z, Lillicrap, DP, Kaufman, RJ et al. (2004). Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice. Mol Ther 10: 117-126. (Pubitemid 38878154)
6. Moayeri, M, Hawley, TS and Hawley, RG (2005). Correction of murine hemophilia A by hematopoietic stem cell gene therapy. Mol Ther 12: 1034-1042. (Pubitemid 41723037)
7. Jiang, H, Lillicrap, D, Patarroyo-White, S, Liu, T, Qian, X, Scallan, CD et al. (2006). Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 108: 107-115. (Pubitemid 43990618)
8. McCormack, WM Jr, Seiler, MP, Bertin, TK, Ubhayakar, K, Palmer, DJ, Ng, P et al. (2006). Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model. J Thromb Haemost 4: 1218-1225.
9. Waters, B and Lillicrap, D (2009). The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. J Thromb Haemost 7: 1446-1456.
10. Miao, CH (2007). Recent advances in immune modulation. Curr Gene Ther 7: 391-402. (Pubitemid 47595781)
11. Herzog, RW and Dobrzynski, E (2004). Immune implications of gene therapy for hemophilia. Semin Thromb Hemost 30: 215-226. (Pubitemid 38582325)
12. Sakaguchi, S, Ono, M, Setoguchi, R, Yagi, H, Hori, S, Fehervari, Z et al. (2006). Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212: 8-27. (Pubitemid 44116697)
13. Belkaid, Y (2007). Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol 7: 875-888. (Pubitemid 350006238)
14. Hawrylowicz, CM and O'Garra, A (2005). Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol 5: 271-283. (Pubitemid 40516153)
15. Wu, K, Bi, Y, Sun, K and Wang, C (2007). IL-10-producing type 1 regulatory T cells and allergy. Cell Mol Immunol 4: 269-275.
16. Shevach, EM, DiPaolo, RA, Andersson, J, Zhao, DM, Stephens, GL and Thornton, AM (2006). The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol Rev 212: 60-73. (Pubitemid 44116700)
17. Izcue, A, Coombes, JL and Powrie, F (2006). Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev 212: 256-271. (Pubitemid 44116713)
18. Belkaid, Y, Blank, RB and Suffia, I (2006). Natural regulatory T cells and parasites: a common quest for host homeostasis. Immunol Rev 212: 287-300. (Pubitemid 44116715)
19. Rouse, BT, Sarangi, PP and Suvas, S (2006). Regulatory T cells in virus infections. Immunol Rev 212: 272-286. (Pubitemid 44116714)
20. Aluvihare, VR, Kallikourdis, M and Betz, AG (2004). Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 5: 266-271. (Pubitemid 38332123)
21. Beyer, M and Schultze, JL (2006). Regulatory T cells in cancer. Blood 108: 804-811. (Pubitemid 44154611)
22. Miao, CH (2010). Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells. Expert Rev Hematol 3: 469-483.
23. Miao, CH, Harmeling, BR, Ziegler, SF, Yen, BC, Torgerson, T, Chen, L et al. (2009). CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice. Blood 114: 4034-4044.
24. Almeida, AR, Borghans, JA and Freitas, AA (2001). T cell homeostasis: thymus regeneration and peripheral T cell restoration in mice with a reduced fraction of competent precursors. J Exp Med 194: 591-599. (Pubitemid 32844770)
25. Curotto de Lafaille, MA, Lino, AC, Kutchukhidze, N and Lafaille, JJ (2004). CD25- T cells generate CD25+Foxp3+ regulatory T cells by peripheral expansion. J Immunol 173: 7259-7268. (Pubitemid 39628162)
26. Boyman, O, Kovar, M, Rubinstein, MP, Surh, CD and Sprent, J (2006). Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311: 1924-1927.
27. Webster, KE, Walters, S, Kohler, RE, Mrkvan, T, Boyman, O, Surh, CD et al. (2009). In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med 206: 751-760.
28. Liu, R, Zhou, Q, La Cava, A, Campagnolo, DI, Van Kaer, L and Shi, FD (2010). Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia. Eur J Immunol 40: 1577-1589.
29. Boyman, O, Surh, CD and Sprent, J (2006). Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin Biol Ther 6: 1323-1331. (Pubitemid 44875686)
30. Tang, Q, Adams, JY, Penaranda, C, Melli, K, Piaggio, E, Sgouroudis, E et al. (2008). Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28: 687-697.
31. Kamimura, D, Sawa, Y, Sato, M, Agung, E, Hirano, T and Murakami, M (2006). IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb. J Immunol 177: 306-314. (Pubitemid 43939142)
32. Miao, CH, Ye, P, Thompson, AR, Rawlings, DJ and Ochs, HD (2006). Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice. Blood 108: 19-27. (Pubitemid 43990608)
33. Cao, O, Loduca, PA and Herzog, RW (2009). Role of regulatory T cells in tolerance to coagulation factors. J Thromb Haemost 7 Suppl 1: 88-91.
34. Peng, B, Ye, P, Blazar, BR, Freeman, GJ, Rawlings, DJ, Ochs, HD et al. (2008). Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice. Blood 112: 1662-1672.
35. Cantrell, DA and Smith, KA (1983). Transient expression of interleukin 2 receptors. Consequences for T cell growth. J Exp Med 158: 1895-1911. (Pubitemid 14210794)
36. Cantrell, DA and Smith, KA (1984). The interleukin-2 T-cell system: a new cell growth model. Science 224: 1312-1316. (Pubitemid 14113627)
37. Taniguchi, T and Minami, Y (1993). The IL-2/IL-2 receptor system: a current overview. Cell 73: 5-8. (Pubitemid 23115443)
38. Setoguchi, R, Hori, S, Takahashi, T and Sakaguchi, S (2005). Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201: 723-735. (Pubitemid 40395118)
39. D'Cruz, LM and Klein, L (2005). Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 6: 1152-1159. (Pubitemid 41541793)
40. Fontenot, JD, Rasmussen, JP, Gavin, MA and Rudensky, AY (2005). A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6: 1142-1151. (Pubitemid 41541792)
41. Ponpuak, M, Davis, AS, Roberts, EA, Delgado, MA, Dinkins, C, Zhao, Z et al. (2010). Delivery of cytosolic components by autophagic adaptor protein p62 endows autophagosomes with unique antimicrobial properties. Immunity 32: 329-341.
42. Wan, YY and Flavell, RA (2005). Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc Natl Acad Sci USA 102: 5126-5131.
43. Finkelman, FD, Madden, KB, Morris, SC, Holmes, JM, Boiani, N, Katona, IM et al. (1993). Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol 151: 1235-1244. (Pubitemid 23219259)
44. Létourneau, S, van Leeuwen, EM, Krieg, C, Martin, C, Pantaleo, G, Sprent, J et al. (2010). IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc Natl Acad Sci USA 107: 2171-2176.
45. Marie, JC, Letterio, JJ, Gavin, M and Rudensky, AY (2005). TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 201: 1061-1067. (Pubitemid 40524674)
46. Peng, B, Ye, P, Rawlings, DJ, Ochs, HD and Miao, CH (2009). Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy. Blood 114: 4373-4382.
47. Bi, L, Sarkar, R, Naas, T, Lawler, AM, Pain, J, Shumaker, SL et al. (1996). Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 88: 3446-3450. (Pubitemid 26365578)
48. Miao, CH, Ye, X and Thompson, AR (2003). High-level factor VIII gene expression in vivo achieved by nonviral liver-specific gene therapy vectors. Hum Gene Ther 14: 1297-1305. (Pubitemid 37174754)
49. Kasper, CK, Aledort, L, Aronson, D, Counts, R, Edson, JR, van Eys, J et al. (1975). Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 34: 612.
50. Belghith, M, Bluestone, JA, Barriot, S, Mégret, J, Bach, JF and Chatenoud, L (2003). TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 9: 1202-1208. (Pubitemid 37173706)